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Abstract
Colistin is a complex polypeptide antibiotic composed mainly of colistin A and B. It was abandoned from clinical
use in the 1970s because of significant renal and, to a lesser extent, neurological toxicity. Actually, colistin is
increasingly put forward as salvage or even first-line treatment for severe multidrug-resistant, Gram-negative
bacterial infections, particularly in the intensive care setting. We reviewed the most recent literature on colistin
treatment, focusing on efficacy and toxicity issues. The method used for literature search was based on a PubMed
retrieval using very precise criteria.
Despite large variations in dose and duration, colistin treatment produces relatively high clinical cure rates. Colistin
is potentially nephrotoxic but currently used criteria tend to overestimate the incidence of kidney injury.
Nephrotoxicity independently predicts fewer cures of infection and increased mortality. Total cumulative colistin
dose is associated with kidney damage, suggesting that shortening of treatment duration could decrease the
incidence of nephrotoxicity. Factors that may enhance colistin nephrotoxicity (i.e., shock, hypoalbuminemia,
concomitant use of potentially nephrotoxic drugs) must be combated or controlled. Neurotoxicity does not seem
to be a major issue during colistin treatment. A better knowledge of colistin pharmacokinetics in critically ill
patients is imperative for obtaining colistin dosing regimens that ensure maximal antibacterial activity at minimal
toxicity.
Introduction
Colistin belongs to the polymyxin class of cationic poly-
peptide antibiotics. It is administered as the prodrug
colistimethate sodium (CMS), a fraction of which is
hydrolyzed in vivo to colistin. During the 1970s, the
popularity of colistin rapidly faded because of reports of
significant renal and neurological toxicity and it was
progressively supplanted by less toxic antibiotics with a
comparable or broader antibacterial spectrum. However,
the mounting prevalence worldwide of infections due to
multidrug-resistant (MDR) Gram-negative bacilli has
renewed interest into colistin but also revived the dis-
cussion about its toxicity [1].
We searched the PubMed database for English lan-
guage studies (a) published during the last 15 years
(from January 1995 to December 2010); (b) including at
least 10 critically ill adult patients without cystic fibrosis
treated with intravenous CMS as primary or salvage
therapy for MDR Gram-negative organisms; and (c)
reporting data on efficacy, nephrotoxicity, and neuro-
toxicity. A total of 26 relevant studies [2-27] were iden-
tified and are summarized in Table 1.
Patient characteristics
The majority of patients were hospitalized in general or
specialized intensive care units (ICU). Patients were
mainly treated for pulmonary, catheter-related or pri-
mary bloodstream, urinary tract, (surgical) wound, and
abdominal and central nervous system infections. The
most frequently isolated pathogens were MDR Acineto-
bacter baumannii and Pseudomonas aeruginosa.S o m e
overlap between studies is present. Kallel et al. evaluated
CMS treatment in a wide array of infections [10] but
also more specifically discussed a subgroup of patients
with ventilator-associated pneumonia [14]. The large
cohort study by Falagas et al. [25] included data on 108
patients, which were reported in previous studies from
the same group [5,7,16]. Severity of illness, as deter-
mined by the APACHE II score, was very different
between studies, which underline the individual impact * Correspondence: herbert.spapen@uzbrussel.be
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provided the original work is properly cited.Table 1 Dosage, duration, outcome, and toxicity of intravenous colistimethate sodium in critically ill patients
Author Patients (N) APACHE II (mean
± SD)
CMS dose/duration [mean ± SD or
median (range)]
Clinical cure
N (%)
Nephrotoxicity
N (%)
Neurotoxicity
Levin 59 (60
infections)
13.1 ± 7 152.8 mg ± 62.8 mg
12.6 ± 6.8 days
35 (58.3) 22 (37) none
Markou 24 (26
infections)
20.6 (mean) 3 MIUq8h
13.5 days (4-24 days)
17 (65.4) 3 (14.5) none
Garnacho-
Montero
21 19.6 ± 7.2 2.5 mg-5 mg/kg/day
14.7 ± 4.1days
12 (57.1) 5 (24) none
Michalopoulos 43 25.8 ± 7.7 3 MIUq8h
18.6 ± 5.8 days
32 (74) 8 (18.6) none
Falagas 17 (19
infections)
14 (median)
43.4 ± 14.6 days
4.4 MIU ± 2.1 MIU 14 (74) 1 (5.2) 1
Kasiakou 50 (54
infections)
16.1 ± 6.1 4.5 MIU ± 2.3 MIU
21.3 ± 16 days
36 (66.7) 4 (8) 1
a
Reina 55 21 ± 7 5 mg/kg (max 300 mg/day)
13 ± 5 days
NA 0 (0) none
Petrosillo
b 14 NA 2 MIUq8h
12 days (mean)
9 (64) 1 (7.1) none
Kallel 75 (78
infections)
NA (SAPS II 37 ±
14)
5.5 MIU ± 1.1
MIU
9.3 ± 3.8 days
60 (76.9) 7/52
(13.5)
1
Koomanachai 78 21.9 (mean) 179.6 mg/day (mean)
11.9 days (mean)
63 (80.8) 24 (30.8) none
Betrosian 15 14 ± 2 5.83 MIU ± 2.3 MIU
duration NA
9 (60) 5 (33) none
Bassetti
b 29 17 ± 3.7 2 MIUq8h
17.7 ± 10.4 days
22 (76) 3 (10) none
Kallel 60 NA (SAPS II 35 ±
12)
2 MIUq8h
9.5 ± 3.8 days
45 (75) 0 (0) NA
Falagas 21 19 ± 4 5.5 MIU ± 1.9 MIU
17.7 ± 11.7 days
11 (52.4) 3 (14.3) none
Falagas 14 (CMS
mono)
14.3 ± 7.4 4.6 MIU ± 2.3 MIU
14.2 ± 7.3 days
12 (85.7) 0 (0) NA
57 (CMS
+MERO)
15.4 ± 6.6 5.5 MIU ± 2.2 MIU
17.8 ± 11.4 days
39 (68.4) 4 (7) NA
Pintado 60 11.2 ± 7.7 4.42 MIU ± 1.39 MIU
20 ± 9.2 days
43 (71.7) 6/55 (10.9) none
Sabuda 12 NA 3.7 mg/kg
14.7 ± 13.8 days
8 (66.7) 5 (41.6) 4 cases
Huang 15 14.7 ± 4.5 1.28 MIU ± 0.25 MIU
22.3 ± 6.2 days
11 (73.3) 0 (0) none
Hartzell 66 8.3 ± 6.5 4.3 ± 1.2 mg/kg/day
15.8 ± 9.2 days
NA 30 (45) 2 cases
Kim 42 (47
infections)
NA 2.25 g (0.6-8.7g)
c
16.6 ± 14.8 days
e
10/15 (66)
d 15 (31.9) none
Kwon 71 NA 4.6 mg/kg (median)
13 days (7-22 days)
NA 38 (53.5) none
Cheng 115
f 6 (median) dose NA
12 ± 7days
g
59 (51) 12/84 (14) 4 cases
Song 10 NA 150 mg q12h
8.1 ± 1.8 days
7 (70) 0 (0) none
Falagas
h 258 17 (range 2-39) up to 3 MIUq8h
mean 17.9 days (10-22)
204 (79.1) 26 (10) NA
Kofteridis 43 17.7 ±7.6 3 MIUq8h
median 10 days (4-36 days)
14 (32.5) 8 (19) none
DeRyke 30 13 (range 7-18)
i 5.1 ± 2 mg/kg/day
j
median 8 days (3-24)
NA 10 (33%) none
NA = not available; APACHE II = Acute Physiology and Chronic Health Evaluation II score; SAPS 2 = Simplified Acute Physiology Score 2; MIU = million
International Units; CMS = colistimethate sodium; MERO = meropenem.
aSame patient as in reference 6;
b+ rifampicine;
cmean cumulative CMS dose when nephrotoxicity occurred;
din patients presenting nephrotoxicity;
ein patients
presenting nephrotoxicity (vs. 9.5 ± 5.6 days in patients without nephrotoxicity, p = 0.07);
f31 patients on renal replacement therapy at start of CMS treatment;
gin patients with good clinical response (vs. 11 ± 11 days in patients with poor response);
hincludes data on 108 patients from references 5, 7, and 16;
iin
patients who developed nephrotoxicity;
j based on ideal body weight.
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renal dysfunction, shock, and respiratory failure.
Dose, duration, and efficacy of colistimethate
sodium treatment
CMS was mostly administered for 10 to 14 days. Dose
regimens varied considerably and were kept constant
daily over time or adapted to the patients’ weight. Doses
were adjusted for renal function depending on serum
creatinine levels or creatinine clearance. CMS was used
as monotherapy, in association with synergistic antibio-
tics (e.g. rifampicin) or in combination with other
broad-spectrum antimicrobials. Clinical efficacy and
toxicity of CMS were evaluated regardless of whether
CMS was prescribed as monotherapy or in combination
with other agents. Global clinical cure for all infections
taken together in all evaluable patients approached 70%.
The largest single-center cohort study to date retrospec-
tively investigated 258 patients with microbiologically
documented infection [25]. Patients were treated for at
least 72 h with intravenous CMS, either alone or in combi-
nation with other antibiotics, and were evaluated during a
7-year period (2000-2007). Because few patients developed
significant nephrotoxicity, the investigators progressively
increased daily CMS doses over time, reaching a standar-
dized protocol of 9 million IU per day (in 3 divided doses)
during the last 2 years of the study. CMS dose was always
adapted to renal function. Infection was cured in 79.1% of
patients. Independent factors for a favorable infection out-
come were antimicrobial regimens that consisted of CMS
in monotherapy or in combination with meropenem
(compared with CMS combined with other agents with
potential activity against the isolated pathogen) and pneu-
monia (compared with bacteremia and abdominal infec-
tion), whereas age and proportional increase in creatinine
independently predicted unfavorable infection outcome.
Lower mean colistin daily dose (3 million IU compared
with 6 and 9 million IU), APACHE II score, hematological
disease, and nephrotoxicity were independent factors pre-
dicting increased mortality.
Nephrotoxicity
Renal toxicity is the most common adverse effect of
colistin treatment because the drug is excreted primarily
by the kidneys and elevated blood levels may further
impair renal function. Little information is available on
the mechanism of toxicity but in vitro electrophysiologi-
cal studies demonstrate that, at long exposure times,
colistin is directly toxic to mammalian urothelium by
increasing transepithelial conduction [28].
A disparity between old and recent studies exists in
the reported rates of nephrotoxicity associated with
intravenous administration of colistin [29]. The recent
studies generally indicate a relatively lower incidence of
renal toxicity. This can be explained by the use of more
purified colistin, the use of colistimethate instead of
c o l i s t i ns u l p h a t e ,m o r ea d e q u a t ed o s ea d j u s t m e n t
according to renal function and significant improvement
of ICU monitoring (in particular of the patient’sh y d r a -
tion status) and treatment (more rapid and adequate
resuscitation of severe sepsis and shock and avoidance
of concomitant administration of potentially nephrotoxic
agents).
Nephrotoxicity rates vary widely, ranging between 0%
and 53.5% [2-27], but comparison between studies is
hazardous and complicated by a lack of control for risk
factors and a case mix of patients with and without
renal dysfunction at baseline. Moreover, the wide range
of reported nephrotoxicity rates probably reflects more
the varying definitions of “renal failure” than the actual
effect of colistin. In studies that discriminate between
patients with normal and impaired renal function before
start of colistin treatment, the incidence of nephrotoxi-
city was 2.5- to 7-fold higher in patients with baseline
renal dysfunction [2,5,7]. Koomanachai et al. reported a
30.8% incidence of nephrotoxicity [11]. However, 70% of
their patients had underlying or predisposing factors
(chronic kidney disease, nephrotoxic drug use, hypovole-
mia), which might have contributed to a decline in renal
function. Also, 58% of the patients were not treated in
an ICU environment despite a high mean APACHE II
score for the whole group. Nephrotoxic effects were
mild and reversible, and no patient required renal repla-
cement therapy. A Canadian study reported at least a
doubling of serum creatinine in 5 of 12 patients (41.6%)
treated with intravenous CMS for at least 3 days [18].
Once again, these patients had severe underlying dis-
eases and comorbidities and all but one received at least
one other potentially nephrotoxic drug. The only patient
with renal failure admitted to the ICU even had received
the equivalent of 13 million IU of colistin per day. It is
noteworthy that the effectiveness and nephrotoxic
potential of intravenous CMS was not different from
imipenem in two studies comparing both antibiotics in
the treatment of ventilator-associated pneumonia [4,14].
Three recent studies used the RIFLE (Risk - Injury -
Failure - Loss - End stage renal disease) classification to
determine CMS-associated nephrotoxicity [20,22,27].
The RIFLE criteria (Table 2) represent an extensively
validated tool for evaluation of acute kidney injury, ran-
ging from mild renal dysfunction to need for renal
replacement therapy [30,31]. Hartzell et al. retrospec-
tively reviewed 66 young adult patients who received
intravenous CMS for at least 3 days [20]. Overall, 30
(45%) patients exhibited criteria for nephrotoxicity at
the time of peak creatinine level (Risk: 13 patients;
Injury: 10 patients; Failure: 7 patients). In 21% of the
patients, CMS was stopped because of nephrotoxicity.
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month after the last CMS dose, criteria for Risk and
Injury were still present in respectively 14 (28%) and 1
(2%) of 50 evaluable patients. In accordance with other
studies [15,27,32,33], kidney injury was found to be
related to the total cumulative dose and the duration of
CMS therapy. Kwon et al. determined the incidence of
CMS-associated kidney injury in 71 adult patients
receiving CMS for more than 3 days [22]. Thirty-eight
(53.5%) patients experienced nephrotoxicity (Risk: 11
patients; Injury: 10 patients; Failure: 17 patients). Com-
pared with the study of Hartzell et al. [20], these
patients were older, more severely ill, and also had
chronic kidney disease or comorbidities predisposing
them to renal toxicity. Cumulative dose of CMS was
lower, probably because the dosage was more frequently
modified for renal impairment. After discontinuation of
CMS, renal function recovered completely in 16 (42%)
patients. Cox regression analysis based on the cumula-
tive dose of CMS identified four independent factors
predicting acute CMS-induced kidney injury: male sex,
concomitant use of a calcineurin inhibitor, hyperbilirubi-
nemia, and hypoalbuminemia. The incidence of kidney
injury increased with an increase in the number of risk
factors. Hypoalbuminemia also was identified as an
independent risk factor for CMS-induced nephrotoxicity
in another study [21]. It is hypothesized that high serum
levels of free colistin might enhance renal toxicity in
patients with low albumin levels. Hypoalbuminemia also
may reflect the severity of the underlying illness. Finally,
DeRyke et al. retrospectively studied 30 patients treated
with CMS for at least 48 h [27]. Nephrotoxicity was
observed in ten (33%) patients (Injury: 3 patients; Fail-
ure: 5 patients; End-stage: 2 patients). Patients who
developed nephrotoxicity were older, had more shock,
and received excessive daily doses of colistin.
All studies using the RIFLE criteria reported a consid-
erably higher incidence of CMS-induced nephrotoxicity
[20,22,27]. A possible explanation may be the very high
sensitivity of the RIFLE criteria, identifying acute kidney
injury at creatinine values that are largely below the cri-
tical levels used to define renal failure (mostly above 1.3
to 2 mg/dL) in the other studies. However, it is striking
that the studies reporting the highest incidence of
colistin-associated nephrotoxicity [18,20,22,27] used pro-
ducts containing 150 mg of “colistin base activity.” This
has important implications for therapeutic dosing
because 150 mg of colistin base corresponds with
approximately 400 mg (or 5 million IU) of CMS. Given
that many patients included in these studies had some
degree of renal dysfunction at baseline or were treated
for prolonged periods of time, it is possible that the
observed nephrotoxicity was caused by “overdosing”
with CMS. This is particularly obvious in the study of
DeRyke et al. [27] where dose calculations based on
actual body weight resulted in daily CMS doses of up to
25 million IU in some patients!
In summary, CMS has nephrotoxic effects but its
potential to injure the kidney is probably overestimated
particularly when very sensitive criteria (i.e., the RIFLE
classification) are used. CMS-induced nephrotoxicity is
mostly mild and reversible. Renal replacement therapy is
occasionally required and permanent kidney damage is
rarely seen. Still, deteriorating renal function remains an
independent factor predicting treatment failure and
increased mortality. Factors that may potentiate renal
toxicity in an ICU setting, such as concomitant nephro-
toxic medication, sepsis, shock, and hypoalbuminemia,
should be adequately controlled. Rigorous application of
recently highlighted measures designed to prevent kid-
ney injury and to protect renal function in an ICU
population remains warranted [34]. The observed asso-
ciation between total cumulative colistin dose and kid-
ney damage suggests that shortening the duration of
treatment for specific infections (e.g., pneumonia) could
decrease the incidence of nephrotoxicity. It must be
emphasized that dosage and frequency of colistin
administration must be adjusted for serum creatinine
levels and thus require close monitoring of renal func-
tion. Finally, the decision to stop colistin treatment on
the basis of renal dysfunction must be weighed against
the consequences of withholding a potentially life-saving
antibiotic.
Neurotoxicity
The interaction of colistin with neurons, which have
high lipid content, has been associated with the occur-
rence of peripheral and orofacial paresthesias, visual
Table 2 RIFLE classification (serum creatinine and GFR criteria)
Category Criteria
Risk (R) Increased creatinine level × 1.5 or GFR decrease >25%
Injury (I) Increased creatinine level × 2 or GFR decrease >50%
Failure (F) Increased creatinine level × 3, GFR decrease >75% or creatinine level >4 mg/dL
Loss (L) Persistent acute renal failure or complete loss of function for >4 weeks
ESKD (E) ESKD for >3 months
GFR = glomerular filtration rate; ESKD = end-stage kidney disease
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zures [32]. The most dreaded neurotoxic event, how-
ever, is neuromuscular blockade presenting as a
myasthenia-like syndrome or as respiratory muscle
paralysis producing apnea [35,36]. Potential triggers of
neurotoxicity are hypoxia, concomitant medication
(muscle relaxants, narcotics, sedatives, anesthetic drugs,
and corticosteroids) and impaired renal function. The
incidence of colistin-associated neurotoxicity reported in
the literature before 1975 was approximately 7%, with
paresthesias constituting the main event. Only sporadic
cases of apnea were reported, typically in patients
receiving colistin intramuscularly, suffering acute or
chronic renal failure or treated with medications known
to potentially induce respiratory muscle weakness [29].
More recent studies–all retrospective in design–did not
observe a clear association between colistin treatment
a n dn e u r o t o x i ce v e n t s .F a l a g a se ta l .d e s c r i b e df o u r
patients who had polymyoneuropathy during colistin
treatment [6]. However, three patients already had neu-
rological symptoms before colistin was started and in
the one remaining patient, polyneuropathic symptoms
subsided despite colistin was continued for 11 more
days. Sabuda et al. reported four patients with varying
neurological complaints [18]. All had developed signifi-
cant renal dysfunction during treatment. Two patients
had concomitant neurotoxic medication (gabapentin,
baclofen, and tizanidine) or disorders (multifocal acute
encephalopathy) that might have contributed to their
neurological “distress” (respectively somnolence and ver-
tigo). One patient with respiratory muscle weakness had
received the equivalent of 13 million IU of colistin base
per day for 19 days whilst experiencing a doubling of
plasma creatinine levels. In a cohort of 115 patients,
Cheng et al. identified four cases of potential colistin-
induced neurotoxicity, including three patients with
focal seizures and one patient with altered mentation
[23]. These patients had normal kidney function but
details about concomitant treatment or comorbidities
were not given.
Diagnosis of neurotoxicity is mostly made on clinical
grounds, making it difficult to discriminate between
eventual colistin-induced neurotoxicity and the more
frequently observed “critical illness polymyoneuropathy”
in ICU patients. In only one study, electrophysiological
measurement was performed in a limited number of
patients who had received colistin for at least 7 days.
Among these patients, 50% exhibited typical features
consistent with critical illness polymyoneuropathy, but
none had evidence of neuromuscular junction blockade
[4]. Of note, no cases of clinically significant neurotoxi-
city were observed in a large group of patients with
underlying neurological disease or disorders admitted to
a neurosurgical ICU [11]. Finally, neuromuscular
blockade was never seen in prospective studies evaluat-
ing CMS treatment [2-4,8,12,13,15].
Optimization of colistin therapy in critical illness
The paucity of pharmacologic information regarding
colistin administration in the critically ill highly impedes
the creation of optimal dosing regimens that reconcile
adequate antibacterial activity with minimal toxicity.
Colistin pharmacokinetics are expected to be dramati-
cally altered in critically ill patients, because they are
frequently prone to large swings in distribution volume,
fluctuations in renal clearance, and variable protein
binding. Also, the antibacterial activity of colistin is atte-
nuated in the face of high bacterial loads, as may be
seen in pneumonia [37].
Data on colistin pharmacokinetics in critically ill
patients with pneumonia and/or sepsis obtained by speci-
fic chromatographic assays became recently available
[38-40]. The administration of CMS at a dose of 2 million
IU [40] or 3 million IU [38,39] every 8 h resulted in max-
imum mean steady-state concentrations (Cmax) of colistin
between 2.21 and 2.93 μg/mL. These findings are trou-
blesome, because they indicate that currently prescribed
CMS doses may be inadequate for treatment of infections
caused by pathogens with minimal inhibitory concentra-
tion values in the upper range of the susceptibility break-
point for colistin (2 μg/mL) and could induce the
selection of resistant strains. Whether this has an impact
on clinical cure and/or outcome is not clear. From the
study by Plachouras et al. [39], it is obvious that it takes 2
to 3 days to reach the Cmax of colistin. These authors
speculate that a loading dose of 9 to 12 million IU of
CMS, followed by a maintenance dose of 4.5 million IU
every 12 h would achieve the target Cmax faster with less
frequent administration. It remains to be investigated
whether this will lead to improved treatment efficacy
without raising concern about toxicity. Moreover, a
recent in vitro pharmacodynamic study in a Pseudomo-
nas aeruginosa model showed that dosing regimens
incorporating higher doses of colistin administered less
frequently produced similar bacterial killing at the cost of
a greater emergence of resistance than the conventional
thrice-daily regimen [41].
Conclusions
CMS is mostly prescribed for treatment of MDR Acine-
tobacter baumannii and Pseudomonas aeruginosa. Clini-
cal cure rates are relatively high, especially when
administered as monotherapy or in combination with a
carbapenem. The dose varies considerably between stu-
dies but has become standardized over time to 9 million
IU per day in patients with normal renal function.
CMS is potentially nephrotoxic but the incidence of
kidney injury is probably overestimated by currently
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influenced by manufacturer-dependent differences in
dose recommendations. Although mostly mild and
reversible, a decrease in kidney function must not be
neglected, because it aggravates prognosis. The use of
s e n s i t i v ec r i t e r i at od e t e c tk i d n e yi n j u r yc o u l dp r o v e
beneficial, because they may prompt clinicians to ade-
quately address disease states, metabolic disorders, and
medications that may enhance or precipitate colistin
nephrotoxicity as well as encourage them to adapt CMS
dosage or treatment duration in a timely manner.
Neurotoxicity does not seem to be a major adverse
event accompanying colistin treatment. However, further
studies must determine whether and how colistin inter-
feres with underlying or ICU-acquired neurological dis-
ease (e.g., epilepsy, septic encephalopathy, critical illness
polymyoneuropathy).
More research on colistin pharmacokinetics and phar-
macodynamics in critically ill patients is urgently needed
to guide adequate colistin dosing at the least toxicity.
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